A study published Monday in Nature showed that Merck's COVID-19 pill molnupiravir induces mutations that can lead to new SARS-CoV-2 variants. Numerous doctors and scientists voiced concerns about the drug’s mutagenicity before it was approved in 2021. The Defender LINK in BIO.